We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Spirogen and BioAtla Present Positive Data on Next-Generation Warheads in ADCs Against Cancer
News

Spirogen and BioAtla Present Positive Data on Next-Generation Warheads in ADCs Against Cancer

Spirogen and BioAtla Present Positive Data on Next-Generation Warheads in ADCs Against Cancer
News

Spirogen and BioAtla Present Positive Data on Next-Generation Warheads in ADCs Against Cancer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Spirogen and BioAtla Present Positive Data on Next-Generation Warheads in ADCs Against Cancer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Spirogen and BioAtla LLC announced new data on the use of pyrrolobenzodiazepine (PBD) dimers as warheads in antibody drug conjugates (ADCs) at the annual meeting of the American Association for Cancer Research (AACR) in Washington, DC.

The study evaluated the efficacy of five ADCs against solid and hematological cancer targets.  The hematological target antibody was engineered using BioAtla’s proprietary CIAO™ and BioAcceleration™ technologies and conjugated to Spirogen’s cytotoxic PBD dimers. Trastuzumab ADCs were tested against Her2-expressing human breast cancer in vivo.

For both tumour types data showed that the ADCs achieved durable complete regression and tumor free survival. The PBD dimers were not found to be cross-resistant with widely-used chemotherapeutic agents.

Professor John Hartley, lead author of the study and Director of Pre-clinical Development at Spirogen, said: “Significant activity at remarkably low doses and at low drug-antibody ratios was seen in all tumor types we studied. Antibody-PBD conjugates are the most promising next-generation oncology compounds for clinical development.”

Dr Jay M Short, Chairman and CEO of BioAtla, said: “By pairing our technologies with Spirogen’s warheads, we have achieved affinity and efficient internationalisation of these exciting novel ADCs.”

Advertisement